CJC-1295 & GHRP-6 Blend

Related by research scope · open each to compare

Regulatory detail for this region is not available in the current seed.

Transparent blend · bci-1.0 · never paid-placement

Primary name

CJC-1295 & GHRP-6 Blend

Sequence not available in current seed.

• GHS hazard class on file
• PPE & spill response
• Disposal guidance
• Not-for-human-consumption posture

Short-acting synthetic GHRH(1-29) analog, chemically identical to CJC-1295 apart from lacking the C-terminal drug affinity complex (DAC) moiety, giving it a much shorter circulating exposure than the DAC form and no peer-reviewed human pharmacokinetic characterization to date.

Like CJC-1295, this analog is designed to bind GHRH receptors on pituitary somatotrophs and stimulate pulsatile growth hormone release, using the same set of proteolysis-resistant amino-acid substitutions relative to native human GHRH. Because it lacks the DAC maleimide group, it is not expected to form the covalent albumin adduct that gives the DAC form its multi-day exposure; without that depot mechanism its circulating half-life is expected to more closely resemble unmodified GHRH(1-29) analogs. A 2026 peer-reviewed narrative review (Dominikowski et al., Front Endocrinol, PMID 42395176) states directly that 'CJC-1295 without DAC' remains essentially uncharacterised in the peer-reviewed human literature: no controlled clinical studies have directly evaluated this specific compound in humans, and claims about physiologic GH pulsatility or body-composition effects are extrapolated from related unmodified GHRH(1-29) analogs (e.g., sermorelin) and non-academic sources rather than from direct evidence on this molecule.

Molar mass

3367.9 g/mol

Synthetic hexapeptide GHS-R1a agonist that triggers pulsatile GH release from pituitary somatotrophs; widely used in preclinical secretagogue research.

GHRP-6 is a selective agonist of the growth hormone secretagogue receptor 1a (GHS-R1a), the same receptor activated by the endogenous orexigenic hormone ghrelin. Binding to GHS-R1a on pituitary somatotrophs couples through Gq/11 proteins to activate phospholipase C, generating IP3 and diacylglycerol, which mobilizes intracellular calcium stores and triggers exocytotic release of stored GH. Concurrently, GHRP-6 acts at hypothalamic GHS-R1a to suppress somatostatinergic tone and stimulate endogenous GHRH release, amplifying pituitary GH output through a dual central-pituitary mechanism. Secondary receptor interactions also lead to modest stimulation of cortisol and prolactin secretion, and prominent appetite stimulation via central ghrelin mimicry — effects that distinguish GHRP-6 from more selective secretagogues such as ipamorelin.

Molar mass

873.0 g/mol

How much research exists, and of what maturity — never a verdict on whether it works.

Reading the evidence

• Evidence quality and gaps vary by application — see the cited grades above.
• Indexed-article counts span all evidence tiers, not only completed human trials.
• No first-party human-dosing, efficacy, or benefit claims are made here.

Key reviews & evidence-gap sources

• Dominikowski A, Rękoś Z, Olejarz M, et al. The emerging landscape of performance-enhancing peptides modulating GH-IGF1 axis: bridging the gap between clinical evidence and patient self-administration. Front Endocrinol (Lausanne). 2026;17:1822475. PMID: 42395176. — Narrative review (PubMed pubtype: Journal Article, Review). Covers GHRH analogues including CJC-1295 with/without DAC and GHRPs; closest blend-relevant anchoring review. Not a systematic review. Per this review, human pharmacokinetics of the no-DAC (Mod GRF 1-29) form used in this blend remain uncharacterised in the literature — no specific half-life is established for it; only the DAC-conjugated form (Teichman 2006) has published human PK.
• Sigalos JT, Pastuszak AW. The Safety and Efficacy of Growth Hormone Secretagogues. Sex Med Rev. 2018;6(1):45-53. PMID: 28400207. PMCID: PMC5632578. — Class-level narrative review of GH secretagogues (GHRPs, ibutamoren). Discusses GHRP-6 by name; CJC-1295 not a primary focus. Concludes few long-term rigorously controlled studies exist; concern for decreased insulin sensitivity. Not blend-specific.
• Teichman SL, Neale A, Lawrence B, et al. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. J Clin Endocrinol Metab. 2006;91(3):799-805. PMID: 16352683. — Randomized, placebo-controlled, double-blind ascending-dose trial of CJC-1295 MONOTHERAPY (not the blend) in healthy adults. Studies CJC-1295 WITH DAC specifically — a longer-acting conjugated form distinct from the no-DAC (Mod GRF 1-29) form used in this blend; its ~6-8 day half-life and multi-day GH/IGF-1 elevations do NOT apply to this blend's CJC-1295 component. Most commonly cited human pharmacology study for the CJC-1295 class; does not evaluate GHRP-6 co-administration.

No registered human trials found for this compound.

Status

No registered trials found

Dominant research route: Subcutaneous (SC) — the most-studied and most commonly discussed route for either component individually. No formal pharmacokinetic study of the combined CJC-1295 + GHRP-6 blend as a single unit exists at any route — all PK data above are COMPONENT-level only. Honesty flag: the CJC-1295 in this blend is the short-acting no-DAC form ('Mod GRF 1-29'), per community discussion (see the 'DAC vs no-DAC formulation discussion' theme) — a materially different molecule/PK profile from the long-acting DAC-conjugated CJC-1295 studied in Teichman et al. 2006, the only controlled human PK trial for either component's SC route. No dedicated human PK study of no-DAC CJC-1295 was identified; per a 2026 narrative review (PMID 42395176) its pharmacokinetics remain uncharacterised in the literature.

CJC-1295 WITH DAC: single and multiple SC doses (30–90 μg/kg) in healthy adults (Teichman 2006, Phase I RCT) — but this blend's CJC-1295 component is the short-acting NO-DAC form (Mod GRF 1-29), a distinct molecule from the one Teichman studied; no dedicated human PK study of no-DAC CJC-1295 was identified this pass. GHRP-6: SC administration in human subjects at ~1 μg/kg with dose-dependent GH release (Arvat/Ghigo group).

Bioavailability: Teichman et al. 2006 established that CJC-1295 WITH DAC (Drug Affinity Complex) produced sustained, dose-dependent GH (2–10 fold) and IGF-I (1.5–3 fold) elevations lasting 6–11 days with an estimated half-life of ~6–8 days — but this PK profile belongs to the long-acting DAC-conjugated molecule, NOT the short-acting no-DAC form (Mod GRF 1-29) this blend actually contains. No dedicated pharmacokinetic study of no-DAC CJC-1295 was identified; per a 2026 narrative review (Dominikowski et al., PMID 42395176) its human PK remains uncharacterised in the literature, so only a qualitative 'short-acting' descriptor is supported here — no specific half-life is asserted for the no-DAC form. GHRP-6 SC peaks within ~30–60 min with a short half-life.

SC is the most-studied route for either component individually, but the load-bearing CJC-1295 PK data (Teichman 2006) is for the DAC-conjugated form, not the no-DAC form this blend actually contains — a materially different molecule/PK profile. GHRP-6 SC data is from human pharmacodynamic studies (Arvat/Ghigo group).

GHRP-6: IV bolus (1 μg/kg) in human subjects for GH-response studies; a PK study of GHRP-6 IV bolus (100, 200, 400 μg/kg) in 9 male healthy volunteers is reported in the secondary literature, but the primary ScienceDirect record could not be independently re-confirmed this pass (HTTP 403 on fetch).

Bioavailability: IV bolus used as reference route for PK characterization; GHRP-6 IV defined systemic availability and short distribution half-life in healthy volunteers. No CJC-1295 IV data (either form) exist.

IV route studied for GHRP-6 pharmacokinetics and GH dose-response in humans; no IV data for CJC-1295 in the blend context.

GHRP-6: intranasal administration in conscious dogs; intranasal bioavailability estimated 34.4–44.9% relative to IV.

Bioavailability: Intranasal GHRP-6 bioavailability in dogs estimated at 34.4–44.9% (vs IV); significant GH-releasing activity demonstrated via nasal route. No CJC-1295 intranasal data (either form) exist.

Intranasal route studied only in animal (dog) model for GHRP-6; no intranasal data for CJC-1295. D-amino acids at positions 2 and 5 confer partial resistance to enzymatic degradation.

GHRP-6: oral administration (300 μg/kg) studied in children with short stature (Bellone 1995); oral GH-releasing effect observed but with very low bioavailability.

Bioavailability: Oral bioavailability of GHRP-6 is reported by secondary aggregator sources at approximately 0.3% (not independently confirmed from a primary pharmacokinetic study this pass); the primary Bellone et al. 1995 trial found oral dosing (300 μg/kg) did not significantly alter nocturnal GH, ACTH, or cortisol on some measures despite detectable GH release on others. No oral bioavailability data exist for CJC-1295 in either form (DAC or no-DAC).

Oral route studied in humans for GHRP-6 but with negligible bioavailability; no oral data for CJC-1295 (either form). Oral stability ≠ oral absorption — peptide is orally unstable/poorly absorbed.

Animal & human figures are kept visibly separate so studied animal doses are never misread as human guidance.

Sorted A–Z by vendor — never by price

Weekly median $/mg from the live vendor crawl.

Researched storefront prices, bucketed

What each test proves — general guidance, plus this compound's researched purity data

Purity on the current market (researched)

Vendor-published, Janoshik-verified Certificates of Analysis for individual CJC-1295 batches report HPLC purity of 98.178% (CJC-1295 with DAC, Panda Peptides) to 99.624% (CJC-1295 mod GRF 1-29, Chameleon Peptides batch B002). No independent aggregate purity range for the CJC-1295/GHRP-6 blend specifically was located.

Independent labs cited for this compound

No FDA recall specifically targeting a CJC-1295 & GHRP-6 blend product was found. The Tailor Made Compounding warning letter references a voluntary recall of tesamorelin products (not this blend) for incorrect beyond-use dating; no blend-specific recall exists in the retrieved records.

Buyer red-flag checklist

• Neither CJC-1295 nor GHRP-6 is FDA-approved for any human indication; both are unapproved new drugs under section 505(a) of the FD&C Act.
• GHRP-6 is on FDA's 503B Category 2 list of bulk drug substances that may present significant safety risks (added 2023-09-29), citing immunogenicity/aggregation/peptide-impurity concerns.
• CJC-1295 has cycled through interim 503A Category 2 listing, withdrawal, and PCAC review — never FDA-authorized for compounding at any point.
• Both components are listed on the WADA Prohibited List (S2 — Peptide Hormones, Growth Factors and Mimetics) at all times (in- and out-of-competition), as non-specified substances.
• Federal criminal indictment (2012) and FDA warning letter (2020) specifically named CJC-1295 and GHRP-6 in misbranded/unapproved drug distribution.
• Press-reported independent testing found a CJC-1295 vial from one vendor (SwissChems) contained <42% of advertised dose, indicating real underdosing risk in the gray-market peptide supply.
• Products are typically sold labeled 'For Research Use Only' while being marketed/dosed for human use, a pattern FDA has repeatedly cited as deceptive.
• Large-scale smuggling of unapproved peptides into the U.S. (CBP Cincinnati, Dec 2025) indicates substantial gray-market import volume subject to detention under Import Alert 66-41.

GMP vs research-grade: the chemistry (SPPS + HPLC + MS) is identical — the difference is the quality system.

Underdosing / mislabeling: A press-reported independent lab test (referenced via The New Yorker, summarized in a Reddit community thread) found a SwissChems CJC-1295 vial contained less than 42% of the advertised dose; the same vendor's BPC-157 vial reportedly contained lead and TB-500 contained endotoxins. This is press-reported/community-relayed, not a primary independent-lab publication. No quantitative underdosing prevalence rate for the CJC-1295/GHRP-6 blend is available from independent lab aggregates (Janoshik/MZ Biolabs/Finnrick) — honest null.

• Detention Without Physical Examination (DWPE) of Unapproved New Drugs Promoted In The U.S. Authorizes FDA field personnel to detain without physical examination unapproved new drugs promoted in the U.S.; encompasses non-FDA-approved peptides marketed for human use. Last revised 05/19/2026 (published 07/16/2026).66-41
• An RUO label is not an import exemption — CBP judges actual intended use.
• Lyophilized powder is ambient-stable in transit; temperature control needed for > 7-day transit.
• US-warehouse vendors dodge import scrutiny — they cost more but ship more reliably.

Every item dated & sourced

Prohibited at all times (in- and out-of-competition) under WADA's 2026 Prohibited List, Section S2 (Peptide Hormones, Growth Factors, Related Substances and Mimetics), subsection S2.2.4 'Growth hormone releasing factors': CJC-1295 is listed as a GHRH analogue; GHRP-6 (pralmorelin) is listed among the GH-releasing peptides (GHRPs). This is a component-level anti-doping classification (WADA schedules substances, not blends). Both are NON-SPECIFIED substances under WADA's classification scheme (the S2 category), carrying strict-liability, four-year-default sanctions.

No granted patents identified in current seed. Composition-of-matter coverage is limited given the peptide's synthetic origin.

• IACUC / IRB research context
• RUO buyer responsibilities & documentation
• Veterinary / alternative-use where lawful
• Jurisdiction-aware "who may lawfully obtain"

What people discuss

Reported concerns — discussion, not established effects

Reading caveats

• Self-experimentation community (bodybuilding/PED forums) — efficacy claims not clinically validated
• Survivorship bias toward positive logs (negative experiences less likely to be logged long-term)
• Vendor-adjacent content (some forum/affiliate sites host dosing guides alongside product listings)
• Blend-stability concern partly sourced from a single influential forum contributor (datbtrue) cited across multiple threads

Manually researched from reddit, youtube, x— theme weights are research estimates, not live counts; aggregated & de-identified. No individual posts, quotes, or usernames are ever shown.

Relative research / market volume — populated once the activity stream is wired

Inline tooltips for lyophilized, RUO, EU/mg, SPPS, 503A and more.

Toggle plain-language ↔ scientific in the header.

• How to read a COA
• Free base vs acetate
• Understanding evidence grades

A research blend combining the GHRH analog CJC-1295 with the growth-hormone secretagogue GHRP-6. US regulatory status: Research use only. Research use only.

Emitted as JSON-LD: ChemicalSubstance · BreadcrumbList · FAQPage.

• Price-drop & back-in-stock alerts
• Regulatory-change email digest
• Print / share this datasheet